While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

This summary highlights significant health news, covering topics such as HIV treatment during U.S. aid pauses, Pfizer's diversity program legal settlement, AstraZeneca's halted UK investment, data ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

A triple-board-certified MD of lifestyle and obesity medicine lists the foods that will optimize your medication's efficacy and minimize unwanted side effects.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...